相关实验视频

Updated: Mar 13, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

延迟心脏衰老:以PANoptosis为中心的潜在机制和有针对性的干预策略

Yuhe Shu¹, Shan Li¹, Shuyu Yang¹

¹The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, China.

Frontiers in cardiovascular medicine

|March 12, 2026

概括

随着人口的老龄化,心脏衰老加速,造成健康风险. 针对细胞死亡途径PANoptosis,为抗击心脏衰老和改善寿命提供了有前途的新疗法.

科学领域:

心血管生物学心血管生物学
细胞衰老机制细胞衰老机制
分子病理学分子病理学

背景情况:

心脏衰老是一个主要的公共卫生问题,与生活质量和寿命的下降有关.
对于心脏衰老的现有干预措施,如老化药,其有效性有限.
需要新的治疗目标来应对与年龄有关的心脏病负担日益增加.

研究的目的:

审查分子机制和PANoptosis在心脏衰老中的作用.
探索PANoptosis作为与年龄有关的心脏功能障碍的潜在治疗标.
总结证据,将PANoptosis与心肌细胞损失,纤维化和心脏衰老中的炎症联系起来.

主要方法:

关于PANoptosis和心脏衰老的研究文献综述.
对调节心肌细胞中PANoptosis的分子通路的分析.
对针对PANoptosis的临床前干预策略的评估.

主要成果:

综合细胞死亡途径PANoptosis与加速心脏衰老有关.
泛光死通过心肌细胞损失,纤维化和慢性炎症导致心脏功能下降.
针对PANoptosis的有针对性的干预措施在临床前模型中显示出显著的治疗潜力.

结论:

PANoptosis代表了治疗心脏衰老的治疗策略的新和有前途的目标.
了解PANoptosis调节网络对于开发有效的抗衰老心脏疗法至关重要.
对PANoptosis向干预的进一步研究可能会导致与年龄有关的心脏病的新疗法.

关键词:

这就是PANoptosis.心脏衰老的心脏衰老心肌功能障碍是指心肌功能障碍.被编程的细胞死亡.有针对性的干预.

更多相关视频

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

Isolation, Transfection, and Long-Term Culture of Adult Mouse and Rat Cardiomyocytes

Isolation, Transfection, and Long-Term Culture of Adult Mouse and Rat Cardiomyocytes

Published on: October 10, 2020

相关概念视频

Aging

Aging

Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Pharmacodynamics in Geriatric Patients: Effects of Age

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...